212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy
The Readout Loud
00:00
The Read Out Loud Podcast
i think what he was referring to there was this kind of idea that the fda sort of sprung the accelerated approval of adrahelm upon the world without a lot of advanced warning. There was, you know, there was no ability to kind of people to debate about this um. And i guess that's one of the lessons that that rick paster learned from this, is that you you need to kind of warn people and give the the people a chance to to, to think about these things in advance.
Transcript
Play full episode
